Symbiotec Pharmalab IPO enters its second day with 80% subscription and a 34% GMP, indicating strong listing expectations. The Rs 1,757 crore issue offers specialised API and biotechnology exposure, while proceeds will reduce debt. However, premium valuations and moderate return ratios warrant careful consideration despite strong investor interest.
Symbiotec Pharmalab IPO enters its second day with 80% subscription and a 34% GMP, indicating strong listing expectations. The Rs 1,757 crore issue offers specialised API and biotechnology exposure, while proceeds will reduce debt. However, premium valuations and moderate return ratios warrant careful consideration despite strong investor interest.
<iframe src="https://hindustansphere.com/embed/cluster/18a7b24814ceb011eda8c4355d17c706528061c9" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Symbiotec Pharmalab IPO Day 2: GMP signals 34% upside — Should you subscribe?"></iframe>
